Literature DB >> 16367757

Induction of PPARbeta and prostacyclin (PGI2) synthesis by Raf signaling: failure of PGI2 to activate PPARbeta.

Tanja Fauti1, Sabine Müller-Brüsselbach, Mihaela Kreutzer, Markus Rieck, Wolfgang Meissner, Ulf Rapp, Horst Schweer, Martin Kömhoff, Rolf Müller.   

Abstract

A role for the nuclear receptor peroxisome proliferator-activated receptor-beta (PPARbeta) in oncogenesis has been suggested by a number of observations but its precise role remains elusive. Prostaglandin I2 (PGI2, prostacyclin), a major arachidonic acid (AA) derived cyclooxygenase (Cox) product, has been proposed as a PPARbeta agonist. Here, we show that the 4-hydroxytamoxifen (4-OHT) mediated activation of a C-Raf-estrogen receptor fusion protein leads to the induction of both the PPARbeta and Cox-2 genes, concomitant with a dramatic increase in PGI2 synthesis. Surprisingly, however, 4-OHT failed to activate PPARbeta transcriptional activity, indicating that PGI2 is insufficient for PPARbeta activation. In agreement with this conclusion, the overexpression of ectopic Cox-2 and PGI2 synthase (PGIS) resulted in massive PGI2 synthesis but did not activate the transcriptional activity of PPARbeta. Conversely, inhibition of PGIS blocked PGI2 synthesis but did not affect the AA mediated activation of PPARbeta. Our data obtained with four different cell types and different experimental strategies do not support the prevailing opinion that PGI2 plays a significant role in the regulation of PPARbeta.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16367757     DOI: 10.1111/j.1742-4658.2005.05055.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  11 in total

1.  PPARs and lipid ligands in inflammation and metabolism.

Authors:  Gregory S Harmon; Michael T Lam; Christopher K Glass
Journal:  Chem Rev       Date:  2011-10-12       Impact factor: 60.622

Review 2.  Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis.

Authors:  Jeffrey M Peters; Jennifer E Foreman; Frank J Gonzalez
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 3.  Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease.

Authors:  Maria G Belvisi; Jane A Mitchell
Journal:  Br J Pharmacol       Date:  2009-08-24       Impact factor: 8.739

Review 4.  Role of peroxisome-proliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and disease.

Authors:  Jeffrey M Peters; Holly E Hollingshead; Frank J Gonzalez
Journal:  Clin Sci (Lond)       Date:  2008-08       Impact factor: 6.124

5.  Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787.

Authors:  Prajakta S Palkar; Michael G Borland; Simone Naruhn; Christina H Ferry; Christina Lee; Ugir H Sk; Arun K Sharma; Shantu Amin; Iain A Murray; Cherie R Anderson; Gary H Perdew; Frank J Gonzalez; Rolf Müller; Jeffrey M Peters
Journal:  Mol Pharmacol       Date:  2010-06-01       Impact factor: 4.054

6.  The transcriptional PPARβ/δ network in human macrophages defines a unique agonist-induced activation state.

Authors:  Till Adhikary; Annika Wortmann; Tim Schumann; Florian Finkernagel; Sonja Lieber; Katrin Roth; Philipp M Toth; Wibke E Diederich; Andrea Nist; Thorsten Stiewe; Lara Kleinesudeik; Silke Reinartz; Sabine Müller-Brüsselbach; Rolf Müller
Journal:  Nucleic Acids Res       Date:  2015-04-30       Impact factor: 16.971

7.  Time course change of COX2-PGI2/TXA2 following global cerebral ischemia reperfusion injury in rat hippocampus.

Authors:  Lijuan Yu; Bin Yang; Jia Wang; Lei Zhao; Weinan Luo; Qingsong Jiang; Junqing Yang
Journal:  Behav Brain Funct       Date:  2014-11-11       Impact factor: 3.759

8.  The Role of PPARs in Cancer.

Authors:  Keisuke Tachibana; Daisuke Yamasaki; Kenji Ishimoto; Takefumi Doi
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

9.  NO-Donating NSAIDs, PPARdelta, and Cancer: Does PPARdelta Contribute to Colon Carcinogenesis?

Authors:  Gerardo G Mackenzie; Shaheen Rasheed; William Wertheim; Basil Rigas
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

10.  Expression of Prostacyclin-Synthase in Human Breast Cancer: Negative Prognostic Factor and Protection against Cell Death In Vitro.

Authors:  Thomas Klein; Jens Benders; Friederike Roth; Monika Baudler; Isabel Siegle; Martin Kömhoff
Journal:  Mediators Inflamm       Date:  2015-07-27       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.